Medtronic에 대한 매도 수량은 투자자에게 Medtronic의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Medtronic (NYSE:MDT) 주식, 공매도 수량 보고

Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

NVDA

TSLA

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 다소 개선되었음을 보여 주면서 화요일에는 &#34;중립&#34; 영역에 머물렀다.화요일(19일) 미국 증시는 혼조세를 보였으며, 나스닥 지수는 약 1% 상승했다. 이는 투자자들이 우크라이나와 러시아 간의 상승하는 지정학적 우려를 과소평가했기 때문이다.

엔비디아 실적 발표 앞두고 나스닥 1% 상승: 투자심리 개선, 공포·탐욕 지수는 &#39;중립&#39; 영역

화요일(19일) 아침 미국 주식 선물이 상승하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 종목은 다음과 같다. 월마트, 에이컴, 로우스, 심보틱 및 메드트로닉

화요일 주목해야 할 주식: 월마트, 에이컴, 로우스, 심보틱 및 메드트로닉

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 추가로 하락했음을 보여주었고, 월요일에 &#34;중립&#34; 영역에 머물렀다.월요일(18일) 미국 주식은 혼조세를 보인 가운데 나스닥 지수는 세션 중 100포인트 이상 상승했다. 이는 도널드 트럼프 대통령 당선자의 자율주행차 규제 완화 전망 보도에 따라 테슬라(NASDAQ:TSLA) 주식이 5.6% 급등하면서 나스닥도 오른 것이다. 

테슬라 오르면서 나스닥 100p 이상 상승: 투자심리 하락, 공포·탐욕 지수는 &#39;중립&#39; 영역에 머물러

Medtronic PLC

Measurable Data Token - United States Dollar

MEDIA TECHS INC by Media Technologies Inc.

Media Technologies Inc

MEDIA TEK INC by Media Tek Inc.

MANDATUM OYJ U/ADR by MANDATUM OYJ

MediaTek Inc

MEDITERRANEAN TOWERS LTD by Mediterranean Towers LTD

Mediterranean Towers Ltd

Medtronic plc (NYSE:&nbsp;MDT), a global leader in healthcare technology,&nbsp;today announced that Thierry Piéton has been appointed Chief Financial Officer for the company, effective March 3, 2025. He will report to Medtronic Chairman and Chief Executive Officer Geoff Martha and will join the Medtronic Executive Committee. Piéton joins Medtronic from Renault Group, where he has served as Chief Financial Officer since March 2022. Gary Corona, who has been serving as interim CFO, will continue in this role until Piéton joins Medtronic, after which Corona will become Senior Vice President, Corporate Finance and will remain on the Medtronic Executive Committee.

Medtronic Names Thierry Piéton As New CFO, Effective March 2025

WIIM

Medtronic shares are trading higher after the company announced that the Centers for Medicare & Medicaid Services is opening a national coverage analysis for Symplicity Spyral Renal Denervation System.

National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure
<ul>
<li>Milestone is supported by large public health need and robust, long-term data from the SPYRAL-HTN global clinical program</li>
</ul>
GALWAY, Ireland, Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, today announced&nbsp;that the Centers for Medicare &amp; Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. This national coverage analysis was initiated by CMS in response to Medtronic&#39;s request to support Medicare beneficiary access to the Symplicity&trade; Spyral renal denervation (RDN) system, used in the Symplicity blood pressure procedure.

Biotech

General

Medtronic Receives CMS National Coverage Analysis For Symplicity Spyral Renal Denervation System; Expected Completion Date For National Coverage Analysis Is Oct 11

Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for BrainSense&#x2122; Adaptive deep brain stimulation (aDBS) and BrainSense&#x2122; Electrode Identifier (EI), having achieved the standards required by the EU Medical Device Regulation (MDR). In addition, the first programming was completed today, performed by Martijn Beudel, MD, PhD, neurologist and associate professor, Department of Neurology, Amsterdam University Medical Center. This landmark approval and first-in-Europe patient programming demonstrate significant advancements in personalized DBS therapy for people with Parkinson's in Europe, including the UK.

Government

Regulations

Medtronic Gains CE Mark Approval for BrainSense Adaptive DBS, Advancing Parkinson's Treatment in Europe and UK

Barclays analyst Matt Miksic initiated coverage on Anteris Technologies Global Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVR#NASDAQ">AVR</a>) with a <a href="https://www.benzinga.com/quote/AVR/analyst-ratings" target="_blank" rel="noreferrer noopener">Positive rating and a forecast of $22</a>.
The analyst notes that Anteris Technologies&#8217; DurAVR valve system is expected to become the second balloon-expandable transcatheter valve replacement (BEV TAVR) system by 2028
Clinicians show a clear preference for BEV TAVR systems over self-expanding (SEV) systems from Medtronic plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>).
The analyst points out that DurAVR, positioned as an emerging next-gen TAVR player, is on track to capture 4%-5% of the U.S. TAVR market by 2030.
Despite strong data from MDT in 2024, clinicians still favor balloon-expandable (BEV) TAVR systems, of which DurAVR is set to be the second.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42851889/meta-ditches-fact-checking-for-community-notes-zuckerberg-says-opportunity-to-restore-free-expression" rel="noreferrer noopener">Meta Drops Fact-Checking For Community Notes: Zuckerberg Sees &#8216;Opportunity To Restore Free Expression&#8217;</a>
The analyst estimates that in the U.S., around 130,000 isolated aortic valve replacement (AVR) procedures are performed annually, out of about 550,000 patients with symptomatic severe aortic stenosis (ssAS). Additionally, 175,000 new ssAS patients are diagnosed each year, while 100,000 patients die annually due to lack of treatment.
Although TAVR market growth has slowed, the analyst sees the market as underpenetrated and views it as a promising target for the next-gen DurAVR platform.
In addition to its BEV delivery system, DurAVR offers superior hemodynamics and laminar blood flow, combining the best features of leading TAVR platforms for more favorable hemodynamics and a low-profile valve height.
Early clinical evidence suggests that DurAVR could outperform other leading TAVR platforms in areas such as hemodynamics, outcomes in valve-in-valve (VIV) procedures and potentially in long-term durability, thanks to the company&#8217;s proprietary ADAPT tissue technology, Miksic writes.
For FY25, the analyst estimates the company to report a loss of $(1.30) per share.
Price Action: AVR shares are trading higher by 2.67% to $5.760&nbsp;at last check Tuesday.
Read now:
<ul>
<li><a href="https://www.benzinga.com/25/01/42830046/amd-reveals-new-ai-processors-gaming-products-ahead-of-ces-2025-shares-rise" target="_blank" rel="noreferrer noopener">AMD Unveils ‘Next Generation' AI Processors, Gaming Gear Ahead Of CES 2025</a></li>
</ul>
Anteris logo courtesy of company

Equities

Movers

Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst

<a href="https://news.medtronic.com/2025-01-06-Medtronic-receives-CE-Mark-for-leading-transcatheter-pulmonary-valve-replacement-system-for-congenital-heart-disease" title="https://news.medtronic.com/2025-01-06-Medtronic-receives-CE-Mark-for-leading-transcatheter-pulmonary-valve-replacement-system-for-congenital-heart-disease">https://news.medtronic.com/2025-01-06-Medtronic-receives-CE-Mark-for-leading-transcatheter-pulmonary-valve-replacement-system-for-congenital-heart-disease</a>
&nbsp;
Harmony&#x2122; Transcatheter Pulmonary Valve system approval expands minimally invasive treatment options for patients with congenital heart disease across European Union
Medtronic plc, a global leader in healthcare technology, today announced it received CE (Conformité Européenne) Mark for the Harmony&#x2122; Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT). The Harmony TPV system has already been implanted in over 2,200 patients and now has access to help many more patients across the European Union.
The Harmony TPV system is designed to treat patients with RVOT anomalies with severe pulmonary valve regurgitation (PR), a condition where blood leaks back into the right lower chamber of the heart after being pumped into the lungs. Harmony TPV system clinical trials demonstrate ease of implant, conformability to the anatomy, and strong clinical and hemodynamic outcomes for congenital heart disease patients up to three years.

Global

Medtronic Receives CE Mark For Leading Transcatheter Pulmonary Valve Replacement System For Congenital Heart Disease

Medtronic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) short percent of float has fallen 16.13% since its last report. The company recently reported that it has 10.01 million shares sold short, which is 0.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.35 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Medtronic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735068618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Medtronic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Medtronic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Medtronic's peer group average for short interest as a percentage of float is 3.63%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Medtronic's Recent Short Interest

Truist Securities analyst Richard Newitter maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Hold and lowers the price target from $93 to $89.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Medtronic, Lowers Price Target to $89

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$28.7K</td>
<td>19.8K</td>
<td>1.3K</td>
</tr>
<tr>
<td>CADL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.00</td>
<td>$44.6K</td>
<td>1.2K</td>
<td>995</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$25.00</td>
<td>$28.7K</td>
<td>27.4K</td>
<td>566</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$75.00</td>
<td>$70.6K</td>
<td>95</td>
<td>286</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$10.00</td>
<td>$35.2K</td>
<td>5.8K</td>
<td>273</td>
</tr>
<tr>
<td>AMED</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$90.00</td>
<td>$147.5K</td>
<td>6.3K</td>
<td>250</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$580.00</td>
<td>$37.6K</td>
<td>1.0K</td>
<td>148</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$55.00</td>
<td>$26.5K</td>
<td>1.0K</td>
<td>130</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$270.00</td>
<td>$123.5K</td>
<td>217</td>
<td>48</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$105.00</td>
<td>$34.0K</td>
<td>32</td>
<td>32</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option sweep with bearish sentiment. It expires in 37 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $15.00 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $287.0 per contract. There were 19843 open contracts at this strike prior to today, and today 1350 contract(s) were bought and sold. 
• Regarding CADL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>), we observe a call option sweep with bearish sentiment. It expires in 9 day(s) on December 20, 2024. Parties traded 372 contract(s) at a $6.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $44.6K, with a price of $120.0 per contract. There were 1230 open contracts at this strike prior to today, and today 995 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bullish, expiring in 401 day(s) on January 16, 2026. This event was a transfer of 101 contract(s) at a $25.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $285.0 per contract. There were 27415 open contracts at this strike prior to today, and today 566 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a put option sweep that happens to be bearish, expiring in 282 day(s) on September 19, 2025. This event was a transfer of 286 contract(s) at a $75.00 strike. This particular put needed to be split into 34 different trades to become filled. The total cost received by the writing party (or parties) was $70.6K, with a price of $247.0 per contract. There were 95 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option trade with neutral sentiment. It expires in 401 day(s) on January 16, 2026. Parties traded 150 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $35.2K, with a price of $235.0 per contract. There were 5818 open contracts at this strike prior to today, and today 273 contract(s) were bought and sold. 
• Regarding AMED (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>), we observe a put option trade with bearish sentiment. It expires in 37 day(s) on January 17, 2025. Parties traded 250 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $147.5K, with a price of $590.0 per contract. There were 6378 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option sweep that happens to be bullish, expiring in 37 day(s) on January 17, 2025. This event was a transfer of 8 contract(s) at a $580.00 strike. This particular put needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $37.6K, with a price of $4710.0 per contract. There were 1038 open contracts at this strike prior to today, and today 148 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bearish, expiring in 2 day(s) on December 13, 2024. This event was a transfer of 100 contract(s) at a $55.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $265.0 per contract. There were 1033 open contracts at this strike prior to today, and today 130 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 401 day(s) on January 16, 2026. Parties traded 47 contract(s) at a $270.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $123.5K, with a price of $2630.0 per contract. There were 217 open contracts at this strike prior to today, and today 48 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 44 day(s) on January 24, 2025. Parties traded 32 contract(s) at a $105.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $1065.0 per contract. There were 32 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMED

AMGN

CADL

RXRX

TEVA

10 Health Care Stocks Whale Activity In Today's Session

Looking into the current session, Medtronic Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) shares are trading at $85.62, after a 1.06% decrease. Over the past month, the stock fell by 4.53%, but over the past year, it actually increased by 8.32%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1733257847_0.png" alt="Past Year Chart" />

<h3>A Look at Medtronic P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 69.67 in the Health Care Equipment &amp; Supplies industry, Medtronic Inc. has a lower P/E ratio of 26.46. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1733257847_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: Medtronic

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$86.00</td>
<td>$29.5K</td>
<td>72</td>
<td align="right">680</td>
</tr>
<tr>
<td>GEHC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/06/24</td>
<td>$84.00</td>
<td>$41.1K</td>
<td>24</td>
<td align="right">368</td>
</tr>
<tr>
<td>IBRX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$4.50</td>
<td>$25.0K</td>
<td>635</td>
<td align="right">330</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$720.00</td>
<td>$227.0K</td>
<td>99</td>
<td align="right">293</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$26.00</td>
<td>$94.8K</td>
<td>2.4K</td>
<td align="right">168</td>
</tr>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$75.00</td>
<td>$259.5K</td>
<td>533</td>
<td align="right">150</td>
</tr>
<tr>
<td>APLT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.00</td>
<td>$33.0K</td>
<td>6.4K</td>
<td align="right">135</td>
</tr>
<tr>
<td>HROW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$31.9K</td>
<td>776</td>
<td align="right">118</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$240.00</td>
<td>$55.0K</td>
<td>491</td>
<td align="right">114</td>
</tr>
<tr>
<td>PSTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.00</td>
<td>$44.2K</td>
<td>85</td>
<td align="right">110</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we observe a put option sweep with bearish sentiment. It expires in 7 day(s) on December 6, 2024. Parties traded 674 contract(s) at a $86.00 strike. This particular put needed to be split into 44 different trades to become filled. The total cost received by the writing party (or parties) was $29.5K, with a price of $44.0 per contract. There were 72 open contracts at this strike prior to today, and today 680 contract(s) were bought and sold. 
• Regarding GEHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), we observe a put option sweep with neutral sentiment. It expires in 7 day(s) on December 6, 2024. Parties traded 360 contract(s) at a $84.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $41.1K, with a price of $113.0 per contract. There were 24 open contracts at this strike prior to today, and today 368 contract(s) were bought and sold. 
• Regarding IBRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>), we observe a put option sweep with neutral sentiment. It expires in 168 day(s) on May 16, 2025. Parties traded 260 contract(s) at a $4.50 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $25.0K, with a price of $95.0 per contract. There were 635 open contracts at this strike prior to today, and today 330 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bullish sentiment. It expires in 112 day(s) on March 21, 2025. Parties traded 100 contract(s) at a $720.00 strike. The total cost received by the writing party (or parties) was $227.0K, with a price of $2270.0 per contract. There were 99 open contracts at this strike prior to today, and today 293 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bearish, is expiring today. Parties traded 158 contract(s) at a $26.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $94.8K, with a price of $600.0 per contract. There were 2480 open contracts at this strike prior to today, and today 168 contract(s) were bought and sold. 
• Regarding BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we observe a call option sweep with bullish sentiment. It expires in 84 day(s) on February 21, 2025. Parties traded 150 contract(s) at a $75.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $259.5K, with a price of $1730.0 per contract. There were 533 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• Regarding APLT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>), we observe a put option trade with bearish sentiment. It expires in 49 day(s) on January 17, 2025. Parties traded 110 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $33.0K, with a price of $300.0 per contract. There were 6422 open contracts at this strike prior to today, and today 135 contract(s) were bought and sold. 
• For HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we notice a put option sweep that happens to be bullish, expiring in 413 day(s) on January 16, 2026. This event was a transfer of 19 contract(s) at a $50.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $31.9K, with a price of $1680.0 per contract. There were 776 open contracts at this strike prior to today, and today 118 contract(s) were bought and sold. 
• For DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we notice a call option trade that happens to be bearish, expiring in 21 day(s) on December 20, 2024. This event was a transfer of 110 contract(s) at a $240.00 strike. The total cost received by the writing party (or parties) was $55.0K, with a price of $500.0 per contract. There were 491 open contracts at this strike prior to today, and today 114 contract(s) were bought and sold. 
• For PSTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), we notice a call option trade that happens to be bullish, expiring in 49 day(s) on January 17, 2025. This event was a transfer of 100 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $44.2K, with a price of $442.0 per contract. There were 85 open contracts at this strike prior to today, and today 110 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLT

GEHC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HROW

IBRX

PSTX

10 Health Care Stocks With Whale Alerts In Today's Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Stifel raised the price target for Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) from $58 to $65. Stifel analyst Tore Svanberg maintained a Buy rating. Semtech shares closed at $53.44 on Monday. <a href="https://www.benzinga.com/quote/SMTC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities raised the price target for Woodward, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) from $187 to $226. Truist Securities analyst Michael Ciarmoli reiterated a Buy rating. Woodward shares closed at $179.29 on Monday. <a href="https://www.benzinga.com/quote/WWD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays boosted Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) price target from $105 to $109. Barclays analyst Matt Miksic maintained an Overweight rating. Medtronic shares settled at $85.75 on Monday. <a href="https://www.benzinga.com/quote/MDT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo boosted Zoom Video Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) price target from $60 to $70. Wells Fargo analyst Michael Turrin maintained an Underweight rating. Zoom Video shares closed at $89.03 on Monday. <a href="https://www.benzinga.com/quote/ZM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler raised Health Catalyst, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) price target from $11 to $12. Piper Sandler analyst Jessica Tassan reiterated an Overweight rating. Health Catalyst shares closed at $8.52 on Monday.  <a href="https://www.benzinga.com/quote/HCAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc boosted GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) price target from $62 to $74. Keybanc analyst Jason Celino maintained an Overweight rating on the stock. GitLab shares closed at $66.37 on Monday. See how other analysts view this stock.</li>
<li>Deutsche Bank cut the price target for Hubbell Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) from $493 to $473. Deutsche Bank analyst Nicole Deblase downgraded the stock from Buy to Hold. Hubbell shares settled at $463.86 on Monday. <a href="https://www.benzinga.com/quote/HUBB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC boosted Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) price target from $128 to $131. HSBC analyst Saul Martinez downgraded the stock from Buy to Hold. Morgan Stanley shares closed at $133.66 on Monday. <a href="https://www.benzinga.com/quote/MS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo increased the price target for Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) from $100 to $115. Wells Fargo analyst Zachary Fadem maintained an Overweight rating. Starbucks shares closed at $101.84 on Monday. <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler boosted The Allstate Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) price target from $206 to $244. Piper Sandler analyst Paul Newsome maintained an Overweight rating. Allstate shares closed at $202.03 on Monday. <a href="https://www.benzinga.com/quote/ALL/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying SBUX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26090422/image-281-1024x583.png" alt="" class="wp-image-665498" style="width:659px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26090422/image-281-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26090422/image-281-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26090422/image-281-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26090422/image-281.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>

GTLB

HCAT

HUBB

SBUX

SMTC

Starbucks To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday

Barclays analyst Matt Miksic maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Overweight and raises the price target from $105 to $109.

Barclays Maintains Overweight on Medtronic, Raises Price Target to $109

<a href="https://www.medtronic.com/en-us/index.html">Medtronic plc</a>, a global leader in health care technology, announced today that the U.S. Department of Veterans Affairs (VA) has awarded a three-year Indefinite Delivery Indefinite Quantity (IDIQ) contract for <a href="https://www.medtronic.com/en-us/healthcare-professionals/products/digestive-gastrointestinal/gastrointestinal-artificial-intelligence/gi-genius-intelligent-endoscopy-module.html">GI Genius</a>&#x2122; AI-powered endoscopy units, resulting in almost 100 additional units being installed across VA medical centers nationwide. This expansion underscores the ability of Medtronic's proven technology to deliver state-of-the-art care to veterans, aiming to provide gold-standard diagnostic accuracy in colorectal screenings for thousands who served.

Contracts

Medtronic Awarded 3-Year VA Contract To Expand GI Genius AI Technology To Enhance Colorectal Cancer Detection In Veterans

Medtronic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) short percent of float has fallen 4.76% since its last report. The company recently reported that it has 10.18 million shares sold short, which is 0.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.93 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Medtronic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732302924_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Medtronic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Medtronic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Medtronic's peer group average for short interest as a percentage of float is 4.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Bernstein analyst Lee Hambright maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform and raises the price target from $96 to $97.

Bernstein Maintains Outperform on Medtronic, Raises Price Target to $97

Wells Fargo analyst Larry Biegelsen maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Overweight and lowers the price target from $106 to $98.

Wells Fargo Maintains Overweight on Medtronic, Lowers Price Target to $98

New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses.
GALWAY, Ireland, Nov. 20, 2024 /PRNewswire/ -- Medtronic&nbsp;plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance for its new InPen&#x2122; app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera&#x2122; continuous glucose monitor (CGM). The company's Smart MDI system combines its InPen&#x2122; smart insulin pen with its newest Simplera&#x2122; CGM — the company's first disposable, all-in-one CGM that's half the size of previous Medtronic CGMs.
With this clearance, the system will be the first in the market to recommend corrections for missed or inaccurate insulin doses, providing real-time, personalized insights for individuals on multiple daily injection (MDI) therapy.&nbsp;

Medtronic Receives FDA Clearance For New InPen App, Paving The Way For Its Smart MDI System Launch With Simplera CGM

Baird analyst David Rescott maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Neutral and lowers the price target from $96 to $93.

Baird Maintains Neutral on Medtronic, Lowers Price Target to $93

Needham analyst Mike Matson reiterates Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Medtronic

Least shorted S&P 500 stocks in December

Bullish option flow detected in Medtronic (MDT) with 4,449 calls trading, 1.6x expected, and implied vol increasing over 1 point to 17.41%. Feb-25 ...

Medtronic call volume above normal and directionally bullish

Welcome to "Sector Spotlight," where The Fly looks at a new industry every week and highlights its happenings. PHARMA SECTOR NEWS:&nbsp;In 2024, dr...

Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations

The automation industry is revolutionizing how businesses operate, with cutting-edge technologies driving efficiency, precision, and cost savings across sectors. As automation continues to reshape industries, fundamentally sound stocks like RTX Corporation (RTX), Medtronic (MDT), and Parker-Hannifin (PH) are poised to benefit from this growth. Read on… The automation industry is transforming businesses' operations, creating smarter, more efficient systems across multiple sectors like manufacturing, healthcare, and logistics. In an era where cost reduction and streamlined workflows are paramount, industries are increasingly adopting automated solutions to stay competitive and meet growing demands.
As the automation landscape continues to evolve, some companies like RTX Corporation (<a href="https://stocknews.com/stock/RTX/">RTX</a>), Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>), and Parker-Hannifin Corporation (<a href="https://stocknews.com/stock/PH/">PH</a>) are leading the charge and are well-positioned to capitalize on the industry's tailwinds.
By now, we know that the potential for growth in AI and automation is enormous. McKinsey estimates that AI technologies could inject<a href="https://www.mckinsey.com/industries/metals-and-mining/our-insights/ai-the-next-frontier-of-performance-in-industrial-processing-plants"> up to $13 trillion</a> into the global economy by 2030. Whether it's self-driving cars, robotic arms revolutionizing manufacturing, or AI algorithms enabling better decision-making in finance and healthcare, the applications of automation seem boundless. The automation market is forecast to reach $238.01 billion by 2030, growing at a <a href="https://www.industryarc.com/Report/15493/automation-market.html">CAGR of 7.2%</a>.
Moreover, the machine tools market, valued at <a href="https://www.grandviewresearch.com/industry-analysis/machine-tools-market">$97.93 billion in 2024</a>, is projected to grow at a CAGR of 7% through 2030. This growth is driven by innovations like multi-axis robotics and smarter manufacturing techniques that prioritize precision and minimize downtime. As industries continue to embrace these technologies, automation is becoming an indispensable part of the global economy.
Let's dig deeper into the fundamental aspects of the aforementioned stocks in detail:
RTX Corporation (<a href="https://stocknews.com/stock/RTX/">RTX</a>)
RTX is a global provider of systems and services for commercial, armed forces, and governmental clients in the aerospace and defense industries. It operates through three segments: Collins Aerospace; Pratt &amp; Whitney; and Raytheon.
On January 16, RTX secured a $529 million contract to supply the Netherlands with a Patriot air and missile defense system fire unit, replacing one previously donated to Ukraine. This was followed by a $333 million contract awarded on January 13 by the U.S. Navy for producing Standard Missile-6 (SM-6) Block IA missiles.
These contracts underscore RTX's expertise in missile defense systems and its critical role in strengthening national and allied defense capabilities while substantially boosting its revenue streams.
On December 12, 2024, the company paid its shareholders a quarterly dividend of $0.63 per share. RTX pays an annual dividend of $2.52, which translates to a dividend yield of 2.08% at the prevailing price levels. Its four-year average dividend yield is 2.34%. Moreover, its dividend payouts have increased at a CAGR of 7.3% over the past three years.
RTX's trailing 12-month EBITDA margin of 15.90% is 13.8% higher than the industry average of 13.98%. Likewise, its trailing 12-month levered FCF margin of 10.21% is 48.5% higher than the industry average of 6.88%.
During the fiscal third quarter that ended September 30, 2024, RTX's sales increased 49.2% year-over-year to $20.09 billion. Its adjusted operating profit grew 11.3% from the year-ago value to $2.48 billion. Its adjusted net income attributable to common shareowners amounted to $1.47 billion, reflecting an increase of 6.9% from the prior-year quarter. In addition, the company's adjusted EPS came in at $ 1.45, up 16% year-over-year.
Analysts expect RTX's <a href="https://www.investopedia.com/terms/e/eps.asp">EPS</a> and revenue for the fourth quarter ended December 31, 2024, to increase 6.6% and 3.1% year-over-year to $1.38 and $ 20.54 billion, respectively. Moreover, it surpassed the consensus EPS and revenue estimates in each of the trailing four quarters, which is promising.
Over the past year, the stock has gained 42.4% to close the last trading session at $121.11. Also, it has gained 15.4% over the past six months.
RTX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
RTX has an A grade for Momentum and a B for Growth. It is ranked #9 out of 70 stocks in the <a href="https://stocknews.com/category/air-defense/">Air/Defense Services</a> industry.
Beyond what we have stated above, we have also given RTX grades for Value, Stability, Sentiment, and Quality. You can get all the RTX ratings <a href="https://stocknews.com/stock/RTX/">here</a>.
Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>)
Headquartered in Dublin, Ireland, MDT provides healthcare technology solutions. It develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The company operates through four segments: Cardiovascular Portfolio; Neuroscience Portfolio; Medical Surgical Portfolio; and Diabetes Operating Unit.
On January 13, 2025, MDT announced that the Centers for Medicare &amp; Medicaid Services (CMS) had initiated a national coverage analysis for renal denervation, aiming to develop Medicare coverage policy for hypertension treatments. This move supports MDT's Symplicity Spyral RDN system, potentially increasing patient access and strengthening the company's position in the healthcare technology market.
In the same month, buoyed by its strong financial performance, the company paid a dividend of $0.70 per share for the third quarter of fiscal year 2025. It pays an annual dividend of $2.80, which translates to a dividend yield of 3.21% at the prevailing price levels. Its four-year average dividend yield is 2.85%. Moreover, its dividend payouts have increased at a CAGR of 4.1% over the past three years.
The stock's trailing 12-month gross profit margin of 65.40% is 12% higher than the industry average of 58.37%. Likewise, its trailing-12-month EBIT and levered FCF margins of 19.77% and 15.19% are considerably above their respective industry averages of 2.68% and 2.33%.
MDT's revenue increased 5.2% year-over-year to $8.40 billion in the fiscal 2025 second quarter that ended on October 25, 2024. Its non-GAAP operating profit came in at $ 2.04 million, up 1.6% year-over-year. In addition, the company's non-GAAP net income reached $ 1.62 billion or $ 1.26 per share, indicating a marginal increase from the prior year quarter.
The consensus revenue estimate of $8.33 billion for the third quarter (ending January 2025) represents a 2.9% improvement year over year. The consensus EPS estimate of $1.36 for the same period indicates a 4.6% increase from the previous year. The company has an impressive surprise history, surpassing the consensus revenue and EPS estimates in each of the trailing four quarters.
The stock has surged 8.4% over the past six months and 10.3% year-to-date to close the last trading session at $88.08.
MDT's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which equates to Buy in our proprietary rating system.
It has a B grade for Value and Stability. Of the 133 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a>, it is ranked #23. To access MDT's Growth, Momentum, Sentiment, and Quality ratings, <a href="https://stocknews.com/stock/MDT/">click here</a>.
Parker-Hannifin Corporation (<a href="https://stocknews.com/stock/PH/">PH</a>)
PH specializes in motion and control technologies, serving industrial, mobile, and aerospace markets through its Diversified Industrial and Aerospace Systems segments. It offers a wide range of products, including motion-control systems, sealing solutions, filtration, and aerospace components, distributed via OEMs and sales networks worldwide.
On November 4, 2024, PH announced the completion of its divestiture of the North America Composites and Fuel Containment (CFC) Division to SK Capital Partners. This move aligns with the company's strategic focus on core business areas in motion and control technologies.
The stock's trailing-12-month net income margin of 14.47% is 122.6% higher than the industry average of 6.50%. Likewise, its trailing-12-month EBIT and levered FCF margins of 20.25% and 12.38% are 95.9% and 80% above their respective industry average of 10.33% and 6.88%.
PH's net sales increased 1.2% year-over-year to $4.90 billion in the fiscal 2025 first quarter that ended on September 30, 2024. Its income before income taxes grew 6.7% from the year-ago value to $ 875.19 million. The company's adjusted net income attributable to common shareholders came in at $809.79 million, up 4.3% year-over-year, while adjusted EPS rose 4% from the prior year's quarter to $6.20.
Street expects PH's EPS for the fiscal second quarter (ended December 31, 2024) to increase 1.3% year-over-year to $6.23, while its revenue for the same period is expected to be $4.80 billion. In addition, it surpassed the consensus EPS and revenue estimates in each of the trailing four quarters.
Shares of PH have gained 46.8% over the past year and 20% over the past six months to close the last trading session at $669.46.
PH's strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
It has a B grade for Momentum, Stability, and Quality. Within the <a href="https://stocknews.com/category/industrial-equipment/">Industrial – Equipment</a> industry, it is ranked #24 out of 89 stocks. <a href="https://stocknews.com/stock/PH/">Click here</a> to see PH's ratings for Growth, Value, and Sentiment.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
RTX shares closed at $121.11 on Friday, up $0.65 (+0.54%). Year-to-date, RTX has gained 4.66%, versus a 1.96% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/rtx-mdt-ph-3-stocks-leading-the-automation-revolution/>3 Stocks Leading the Automation Revolution</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Stocks Leading the Automation Revolution

Medtronic taps Renault Group's Thierry Piéton as CFO

Medtronic (MDT) announced that Thierry Pieton has been appointed CFO for the company, effective March 3. He will report to Medtronic chairman and C...

Medtronic appoints Thierry Pieton as CFO

An announcement from Medtronic ( ($MDT) ) is now available. Medtronic announced the appointment of Thierry Pieton as Chief Financial Officer effect...

Medtronic Appoints Thierry Pieton as New CFO

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Medtronic (MDT – Research Report). The company's sha...

Truist Financial Sticks to Its Hold Rating for Medtronic (MDT)

Beta Bionics sets terms for upsized $113M IPO

ABBV

ABCL

AMZN

BBNX

CGON

GILD

GOOG

GOOGL

ILMN

ITCI

MSFT

PODD

REGN

RHHBY

RHHVF

RLAY

SCHW

TCHBF

TNDM

Screenshot 2024-10-03 at 5.30.47 PM

Health Care

DXCM

GCTK

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Press Releases

"Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside to Watch"

Small Cap

Opinion

The Intersection of AI, Medicine, and Stocks: A New Era of Opportunities Issued on behalf of Avant Technologies Inc.

Dividends

Medtronic announces cash dividend for third quarter of fiscal year 2025

"Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances"

Why Healthcare Providers Are Increasingly Trusting Artificial Intelligence for Detection & Diagnosis

Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference

Medtronic achieves CE Mark approval for BrainSense™ Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's through innovative brain-computer interface technology

Comments

Medtronic

매도 수량

Medtronic (NYSE:MDT) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌